
    
      Primary Outcome Measure: efficacy and reasonable dosage of the combination of apatinib and
      EGFR-TKI in advanced non-squamous non-small cell lung cancer with EGFR-TKI resistance.

      Secondary Outcome Measures: Progression free survival, overall survival, Side effects.
    
  